Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD)

• Published in: Tissue barriers 2024-07, Vol.12 (3), p.2289830
• Main Authors: Singh, Swati, Kumar, Anit, Gupta, Suruchi, Agrawal, Rohini
• Format: Article
• Language: English
• Subjects: Animals; Humans; NAFLD; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Nrf2; phytoconstituents; PPAR; PPAR gamma - agonists; PPAR gamma - metabolism; Review
• ISSN: 2168-8370; 2168-8362; 2168-8370
• DOI: 10.1080/21688370.2023.2289830

NAFLD is a condition that develops when the liver accumulates excess fat without alcohol consumption. This chronic liver ailment progresses along with insulin resistant and is typically not diagnosed until the patients have cirrhosis. Nuclear hormone receptor superfamily PPARs are essential for metabolism of fatty acids and glucose. In liver, lipid metabolism is regulated by nuclear receptors and PPARα, and PPARβ/δ encourages fatty acid β-oxidation. PPAR-γ, an energy-balanced receptor is a crucial regulator in NAFLD. The partial activation of PPAR-γ could lead to increased level of adiponectin and insulin sensitivity, thus improved NAFLD. Because of less side effects, natural compounds are emerged as potential therapeutic agents for NAFLD by PPARγ agonists. Although the results from preclinical studies are promising, further research is needed to determine the potential dosing and efficacy of mentioned compounds in human subjects. In this review, we summarize the effect of natural PPARγ agonist in the NAFLD.